ArticleBMC microbiology2026
Faecal microbiome and serum metabolomics: potential biomarkers for type 2 diabetes.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundType 2 diabetes (T2D) presents clinical challenges due to its difficult early diagnosis and treatment insensitivity. Further, the relationship between gut microbiota and serum composition in T2D has not been fully characterized. This study aimed to determine the relationship between gut microbiome and serum metabolome in patients with T2D.
methodsWe collected fecal and serum samples from 30 T2D patients and healthy controls (HCs). The fecal microbiome composition was analyzed using 16S rRNA sequencing, and serum metabolites were detected by UHPLC-MS/MS. Alpha and beta diversity indices (Chao1, Shannon, PCoA, etc.) were calculated to assess microbial diversity and community structure. Differential metabolites were integrated to identify potential biomarkers, and random forest modeling was used for predictive analysis to investigate and validate the importance of specific gut microbial genera.
resultsThe feces and blood of T2D patients demonstrated different characteristics of 20 differential microbiomes in the gut and 30 metabolite in the blood from HCs. Further, a significant correlation was observed between the gut microbiota and serum metabolomic profiles, reflecting the influence of the microbiota on metabolic activity. In addition, the states of T2D and HC groups were clearly distinguishable based on differences in gut microbes and metabolites, with the random forest model achieving excellent diagnostic performance (AUC values of 0.9764 and 0.9823, respectively).
conclusionsOur study provides a comprehensive profile of changes in the microbiome and serum metabolomics, indicating their potential application as biomarkers for future diagnosis and treatment in T2D.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.